Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company’s latest dividend increase, declared April 14, highlights how J&J’s post-Kenvue focus on prescription medicines and medical technology has been paired with a steady shareholder payout cadence.
THE APEX TIMES
THE APEX TIMES
At a time when Pfizer shares imply a dividend yield near 6.7%, the company’s latest earnings materials stress preserving the payout through a difficult patent-loss transition, while building confidence in cash flow later in the decade.
THE APEX TIMES
In two pivotal Phase 3 trials, Lilly said its investigational triple-agonist retatrutide drove large weight loss and improved A1C, knee osteoarthritis pain, and moderate-to-severe obstructive sleep apnea severity.
THE APEX TIMES
Eli Lilly’s stock has surged on expectations for its GLP-1 and obesity pipeline, but the company’s own updates highlight how quickly policy, pricing, and uptake can change the outlook.
THE APEX TIMES
The company agreed to buy three infectious-disease developers, adding shingles, bacterial pathogen, and Epstein-Barr virus programs in a bid to build a new long-term prevention business.
THE APEX TIMES
The company said updated findings from pivotal Phase 3 trials of retatrutide were presented this week, reinforcing enthusiasm around a potential triple-agonist approach to weight loss. Details beyond the headline-level results were not included in the cited post.
THE APEX TIMES
A new licensing and collaboration deal with Innovent Biologics is designed to build a pipeline that could help replace revenue as key franchises near loss of patent protection.
THE APEX TIMES
At the American Diabetes Association meeting, Pfizer highlighted Phase 2b results for PF’3944 (berobenatide), an ultra-long-acting GLP-1 receptor agonist designed for once-monthly maintenance dosing - along with early tolerability outlines that will shape how investors weigh Pfizer’s obesity push.
THE APEX TIMES
The deals total up to nearly $4 billion in cash, adding shingles, bacterial infection and Epstein-Barr virus vaccine platforms to Lilly’s pipeline.
